These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11103264)

  • 1. [Roaming through methodology. XXIII. The need for randomization and blinding in therapeutic investigations].
    Dorhout Mees EJ
    Ned Tijdschr Geneeskd; 2000 Nov; 144(46):2228. PubMed ID: 11103264
    [No Abstract]   [Full Text] [Related]  

  • 2. [Roaming through methodology. XXIII. The need for randomization and blinding in therapeutic investigations].
    Knipschild PG
    Ned Tijdschr Geneeskd; 2000 Sep; 144(38):1826-8. PubMed ID: 11020835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experimental studies].
    Gili M; Lacalle JR; Velasco A
    Enferm Infecc Microbiol Clin; 1990 Jan; 8(1):52-7. PubMed ID: 2095906
    [No Abstract]   [Full Text] [Related]  

  • 4. Pre-trial evaluation of the potential for unblinding in drug trials: a prototype example.
    Walter SD; Awasthi S; Jeyaseelan L
    Contemp Clin Trials; 2005 Aug; 26(4):459-68. PubMed ID: 16054578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic equivalence: fallacies and falsification.
    Garrett AD
    Stat Med; 2003 Mar; 22(5):741-62. PubMed ID: 12587103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Continuing education. Clinical trials].
    Sökeland J
    Urologe A; 1990 Nov; 29(6):W41-2. PubMed ID: 2291253
    [No Abstract]   [Full Text] [Related]  

  • 7. Commentary: The debate on non-inferiority trials: 'when meta-analysis alone is not helpful'.
    Liberati A; D'Amico R
    Int J Epidemiol; 2010 Dec; 39(6):1582-3. PubMed ID: 21113051
    [No Abstract]   [Full Text] [Related]  

  • 8. An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methods.
    Devereaux PJ; Choi PT; El-Dika S; Bhandari M; Montori VM; Schünemann HJ; Garg AX; Busse JW; Heels-Ansdell D; Ghali WA; Manns BJ; Guyatt GH
    J Clin Epidemiol; 2004 Dec; 57(12):1232-6. PubMed ID: 15617948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials.
    Soonawala D; Middelburg RA; Egger M; Vandenbroucke JP; Dekkers OM
    Int J Epidemiol; 2010 Dec; 39(6):1567-81. PubMed ID: 20837637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The blind leading the blind: use and misuse of blinding in randomized controlled trials.
    Miller LE; Stewart ME
    Contemp Clin Trials; 2011 Mar; 32(2):240-3. PubMed ID: 21070890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors.
    Haahr MT; Hróbjartsson A
    Clin Trials; 2006; 3(4):360-5. PubMed ID: 17060210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding.
    Hróbjartsson A; Forfang E; Haahr MT; Als-Nielsen B; Brorson S
    Int J Epidemiol; 2007 Jun; 36(3):654-63. PubMed ID: 17440024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. General design issues in efficacy, equivalency and superiority trials.
    Fleiss JL
    J Periodontal Res; 1992 Jul; 27(4 Pt 2):306-13; discussion 323-7. PubMed ID: 1507018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of non-compliance on intent-to-treat analysis of equivalence trials.
    Sheng D; Kim MY
    Stat Med; 2006 Apr; 25(7):1183-99. PubMed ID: 16220491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomization as a basis for inference in noninferiority trials.
    Wiens BL
    Pharm Stat; 2006; 5(4):265-71. PubMed ID: 17128425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The probe methodology can be considered an alternative to randomized double-blind?].
    Dainesi SM
    Rev Assoc Med Bras (1992); 2010; 56(2):132. PubMed ID: 20498979
    [No Abstract]   [Full Text] [Related]  

  • 17. What we can learn from open-label extensions of randomized clinical trials.
    Cummings JL
    Arch Neurol; 2006 Jan; 63(1):18-9. PubMed ID: 16401732
    [No Abstract]   [Full Text] [Related]  

  • 18. [Multiple practice research. Experience with some methods].
    Bennedsen H; Nielsen JV
    Ugeskr Laeger; 1979 May; 141(22):1482-4. PubMed ID: 377745
    [No Abstract]   [Full Text] [Related]  

  • 19. On non-inferiority margin and statistical tests in active control trials.
    Chow SC; Shao J
    Stat Med; 2006 Apr; 25(7):1101-13. PubMed ID: 16345042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The quality of reporting and outcome measures in randomized clinical trials related to upper-extremity disorders.
    Gummesson C; Atroshi I; Ekdahl C
    J Hand Surg Am; 2004 Jul; 29(4):727-34; discussion 735-7. PubMed ID: 15249101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.